Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene, MD Anderson Team on KRAS Mutation Research

NEW YORK (GenomeWeb News) – Trovagene today announced a collaboration with the University of Texas MD Anderson Cancer Center for the detection of transrenal KRAS mutations in the urine of patients with pancreatic cancer.

Trovagene recently completed the analytical development of digital PCR assays for detecting the most common KRAS mutations, including ones accounting for 95 percent of KRAS mutations found in pancreatic adenocarcinomas. According to the San Diego-based firm, KRAS mutations are found in more than 90 percent of pancreatic cancers and in 23 percent of all cancer tissue samples examined by the Sanger Centre.

"The reliable detection and quantification of both KRAS mutations and wild type molecules from urine could eventually lead to a sensitive method for staging tumors before treatment and detecting minimal residual disease after treatment," Charlie Rodi, chief technology officer for Trovagene, which recently raised $10.6 million in a public offering, said in a statement. "The volume of urine that can be collected far outstrips what is available by biopsy or even through blood collection; this may significantly improve detection."

Financial and other terms of the deal were not disclosed.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.